Human dermal fibroblasts - SpinalCyte

Drug Profile

Human dermal fibroblasts - SpinalCyte

Alternative Names: CybroCell

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator SpinalCyte
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Intervertebral disc degeneration

Most Recent Events

  • 09 Feb 2017 The U.S. Patent Office issues Patent to SpinalCyte for human dermal fibroblast
  • 26 Jan 2017 Phase-I clinical trials in Intervertebral disc degeneration (In adult, In the elderly) in USA (Parenteral)
  • 16 Jun 2014 SpinalCyte and Rush University Medical Center agree to co-develop human dermal fibroblast in USA for Intervertebral disc degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top